The melanocortin receptor (MCR) family consists of five receptor subtypes (MC1R-MC5R), endogenous agonists and antagonists. These receptors are involved in important biological pathways such as skin and hair pigmentation, food intake, energy homeostasis, erectile function, and exocrine glands function [1] . The MC3 and MC4 receptors are expressed in the brain and regulate weight and energy homeostasis as well as feeding behavior [2] . Our laboratory is involved in the design, synthesis and characterization of ligands to probe selectivity and potency at these functionally overlapping receptors [3] [4] [5] . The [1,2,3]-triazole-based bridge was previously utilized as a disulfide-bridge replacement in the sunflower trypsin inhibitor-1 peptide [6] . More recently, [1,2,3]-triazole-bridge was introduced into a synthetic melanocortin agonist, MT-II template as a type-I β-turn mimetic [7] . In our ongoing efforts to identify potent and selective lead compounds at melanocortin receptors, we designed and synthesized mono-and bis-triazoles incorporated chimeric AGRP-Melanocortin peptides. It was hypothesized that triazole-bridge may serve as a viable repacement for the disulfide-bridge in the AGRP-melanocortin chimeric peptide template.
Introduction
The melanocortin receptor (MCR) family consists of five receptor subtypes (MC1R-MC5R), endogenous agonists and antagonists. These receptors are involved in important biological pathways such as skin and hair pigmentation, food intake, energy homeostasis, erectile function, and exocrine glands function [1] . The MC3 and MC4 receptors are expressed in the brain and regulate weight and energy homeostasis as well as feeding behavior [2] . Our laboratory is involved in the design, synthesis and characterization of ligands to probe selectivity and potency at these functionally overlapping receptors [3] [4] [5] . The [1,2,3]-triazole-based bridge was previously utilized as a disulfide-bridge replacement in the sunflower trypsin inhibitor-1 peptide [6] . More recently, [1,2,3]-triazole-bridge was introduced into a synthetic melanocortin agonist, MT-II template as a type-I β-turn mimetic [7] . In our ongoing efforts to identify potent and selective lead compounds at melanocortin receptors, we designed and synthesized mono-and bis-triazoles incorporated chimeric AGRP-Melanocortin peptides. It was hypothesized that triazole-bridge may serve as a viable repacement for the disulfide-bridge in the AGRP-melanocortin chimeric peptide template.
Results and Discussion
This study utilized the chimeric peptide template Tyr-c[Cys-His-DPhe-Arg-Trp-Asn-Ala-Phe-Cys]-Tyr-NH2 (AMW3-130), which we previously identified as a subnanomolar potent agonist for the melanocortin receptors [4, 5] . This template is derived from the antagonist hAGRP(109-118) decapeptide sequence with amino acid residues His-Phe-Arg-Trp from the melanocortin agonists incorporated in the place of the Arg-Phe-Phe amino acids. It contains a single disulfide bridge between the two Cys side chains [4, 5] . The cyclic peptide AMW3-130 (Table 1) is equipotent to -MSH at the mMC1R and more potent than -MSH at the mMC4R. Here, we designed 1,4-disubstituted and 1,5-disubstituted mono-[1,2,3]-triazole-bridged cyclic peptides 1, and bis-[1,2,3]-triazole-bridged cyclic peptides 2 (Figure 1 ). Linear peptides were synthesized using microwave-assisted Fmoc-solid phase peptide methodology. Copper(I)-catalyzed intramolecular azide-alkyne cycloaddition was used to afford 1,4-disubstituted [1,2,3]-triazole-bridged cyclic peptides. Ruthenium(II)-catalyzed azide-alkyne cycloaddition was used to obtain 1,5-disubstituted [1,2,3]-triazole-bridged cyclic peptides. The purified peptides were at least 95% pure as determined by RP-HPLC in two diverse solvent systems and possessed the correct molecular weights as determined by mass spectrometry. The synthesized peptides were tested for agonist pharmacology using the cAMP-based AlphaScreen assay at the mouse melanocortin receptors (mMC3R and mMC4R) [8] . This study resulted in several compounds with interesting pharmacology (Table 1 ; Figure 2 ) at mMC3R and mMC4R. The 1,5-disubstituted [1,2,3]-triazolebridged peptide SRT4-79-1cy showed increased agonist activity at the mMC3R and mMC4R compared to the linear compound SRT4-79-2-lin having the azido and alkynyl side chains. Fig. 1. The mono-[1,2,3]-and bis-[1,2,3 ]-triazolebridged cyclic peptides.
The 1,5-disubstituted triazolyl peptide SRT4-79-1cy resulted in equipotent functional activity (within experimental error) at the mMC3R and 5-fold reduced potency at the mMC4R versus the disulfide bridged peptide AMW3-130 ( Table 1 ). The 1,5-disubstituted triazolyl peptide (SRT4-79-1cy) was 4-fold more potent at the mMC3R, but retained equipotency at the mMC4R in comparison to the 1,4-disubstituted triazolyl peptide (SRT4-79-2cy). The bis-[1,2,3]-triazole-bridged peptides SRT4-154-1cy (1,5-disubstituted) and SRT4-154-2cy (1,4-disubstituted) ( Figure 1 ) were designed to improve selectivity at the melanocortin receptors. However, incorporation of the bulky group resulted in reduced agonist potency at both mMC3 and mMC4 receptors (Table 1, Figure 2 ). In conclusion, we synthesized 1,4-and 1,5-disubstituted triazole-bridged macrocyclic peptides using Cu(I)-catalyzed and Ru(II)-catalyzed cycloadditions respectively. We demonstrated that the 1,2,3-triazole-bridge is a viable mimetic for disulfide-bridge replacement in melanocortin chimeric peptide template. These triazole-bridged peptides may serve as a probe for in vivo studies.
